It has recently been claimed that patients who achieve PASI scores less than or equal to 2 within the first 6 months of initiating biologic treatment tend to exhibit more stable psoriasis and a ...

The rates of response were 53%, 61%, and 64% for the 20-mg, 30-mg, ... At 4 weeks, PASI scores climbed from baseline by nearly 40% for those on all orismilast doses, ...

The primary end point was a reduction from baseline of at least 75% in the Psoriasis Area and Severity Index (PASI) score (PASI 75 response; PASI scores range from 0 to 72, with higher scores ...

Of the 230 patients who received continuous deucravacitinib treatment and achieved PASI 75 by week 24, 60.9% achieved PASI 90 and 82.2% achieved sPGA 0/1. Response rates were generally maintained ...

PASI 100 rates at the same time points were 27% and 40% among patients switched from placebo to icotrokinra. IGA 0 response rate increased from 1% at 16 weeks to 23% at 24 weeks, and PASI 100 ...

The proportion of patients who achieved a PASI 100 score, signifying total clearance, approached 70% at 4 years in the group with the greatest response. PASI 90 and PASI 100 rates at this point ...

Although there was no statistically significant difference between the proportion of patients who achieved a PASI-50 response on EDP2939 compared to placebo, it was notable that such numeric ...

A lower PASI when therapy ends (HR, 1.03; 95% CI, 1.01-1.05). This model had good predictive and discriminative ability. The sensitivity analysis showed similar results to the primary analysis.

Meanwhile, 49.6% of patients saw a 90% or more improvement in a Psoriasis Area and Severity Index (PASI 90) score from baseline, meeting the other co-primary goal. Of those on placebo, 4.4% met ...

“The study’s primary endpoint, the difference in the proportion of patients who achieved an outcome of a 50% improvement from baseline in Psoriasis Area and Severity Index (PASI) score (a PASI ...